TwinBeech Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

TwinBeech Capital’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-79,286	Closed	-$41.6M	–	786
2025 Q2	$41.6M	Buy	79,286 +26,185	+49%	+$14.6M	0.94%	24
2025 Q1	$33.7M	Buy	53,101 +27,964	+111%	+$19.2M	0.61%	44
2024 Q4	$17.9M	Sell	25,137 -20,730	-45%	-$17.4M	0.31%	108
2024 Q3	$48.2M	Buy	+45,867	New	+$51M	0.92%	18
2024 Q2	–	Sell	-21,013	Closed	-$20.2M	–	752
2024 Q1	$20.2M	Buy	+21,013	New	+$20M	0.42%	68
2023 Q4	–	Sell	-248	Closed	-$204K	–	869
2023 Q3	$204K	Sell	248 -20,350	-99%	-$16M	﹤0.01%	599
2023 Q2	$14.8M	Buy	20,598 +6,922	+51%	+$5.34M	0.29%	108
2023 Q1	$11.2M	Buy	+13,676	New	+$10.3M	0.23%	136
2020 Q1	–	Sell	-9,507	Closed	-$3.57M	–	435
2019 Q4	$3.57M	Buy	+9,507	New	+$3.2M	1.03%	14

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TwinBeech Capital's REGN Position: Q3 2025 in Review

TwinBeech Capital sold out of Regeneron Pharmaceuticals (REGN) in Q3 2025, closing a stake of 79,286 shares — an estimated $41.6M sold.

TwinBeech Capital first reported a position in REGN in Q4 2019 and held it in 9 quarters. The position peaked at $48.2M in Q3 2024. 1,244 funds tracked by Wall St. Rank hold REGN as of Q3 2025.

TwinBeech Capital reported no remaining Regeneron Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
TwinBeech Capital sold 79,286 Regeneron Pharmaceuticals shares in Q3 2025, an estimated $41.6M.
TwinBeech Capital first reported a position in Regeneron Pharmaceuticals in Q4 2019 and held it in 9 quarters.
TwinBeech Capital's Regeneron Pharmaceuticals position peaked at $48.2M in Q3 2024.
1,244 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2025.

Based on TwinBeech Capital's 13F filing for Q3 2025, filed 14 Nov 2025.